RBM3 Protein and Melanoma Prognosis
Author Information
Author(s): Jonsson Liv, Bergman Julia, Nodin Björn, Manjer Jonas, Pontén Fredrik, Uhlén Mathias, Jirström Karin
Primary Institution: Lund University
Hypothesis
The study investigates the prognostic value of RBM3 protein expression in malignant melanoma.
Conclusion
High nuclear RBM3 expression in primary melanoma is an independent marker of prolonged overall survival.
Supporting Evidence
- RBM3 expression was assessed in 215 out of 226 primary tumors.
- Strong RBM3 expression was significantly associated with favorable clinicopathological parameters.
- High RBM3 expression correlated with prolonged recurrence-free survival and overall survival.
Takeaway
RBM3 is a protein that helps doctors understand how serious melanoma is; more of it in tumors means patients tend to live longer.
Methodology
The study used immunohistochemistry to analyze RBM3 expression in tissue microarrays from melanoma patients.
Potential Biases
Potential bias related to the TMA technique and the selection of cases for analysis.
Limitations
The study may have selection bias due to the population-based cohort design and the use of tissue microarrays.
Participant Demographics
The cohort included 264 individuals, with a mean age of 67.29 years, comprising 51.1% females and 48.9% males.
Statistical Information
P-Value
p < 0.001 for overall survival
Confidence Interval
95% CI = 0.18-0.61 for overall survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website